The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Excellent progress should lead to improved profits going forward and an increasing dividend for this small cash rich high tech company.
Added further to my holding discount to NAV remains to tempting!
Trading on a discount of 17.5% reflecting the sale of Affinium the SP should rise to reflect the average discount which has been 10-12%. Good value at these levels and I have bought today.
Trading at a 30% discount to NAV large holding in ETO which has just posted very good results strong buy IMO.
Excellent results although IMO the best way to take advantage of it is to buy Marwyn Value investors (MVI) who a have a significant holding in ETO and trade at approx 30% discount to their net asset value.
Good T/U the SP should now be capable of breaking through the 50p resistance level IMO.
Tipped by IC there has been a lot of director buying in the last 3 months also Cevian Capital have increased their position significantly. Hoping this starts to head north as it moves closer to its results due on 4 Mar.
After 3 days of trying finally managed to buy some of these online will continue to add where I can. I like these small off the radar value companies especially when you get a dividend.
Always thought this would re rate once Don disappeared.
Tipped by Nick Louth in Money Observer "Just 3% of RUS 1.4m metres of warehousing is vacant income is rising and a lease agreement has been agreed with Dixy (one Russia's largest supermarket chains') in their next warehouse project in Moscow. The company also has plenty of land to build further units and analysts expect the company's NAV to be more than 90p by the end of 2013." IMO Raven has potential upside due to increasing revenues going forward but the downside is limited by the NAV which is based just on the property and land it owns and does not take into account the revenues they produce.
We seem to have this to ourselves still the quiet BB's are often the best ones. Bev88 ASY fits the profile of companies you prefer 90% owned by management who imo put shareholders interests to the fore I have certainly not been disappointed still think DJAN is undervalued.
Added some more to the SIPP still undervalued imo hoping for 10% return over 2014.
Tipped by IC hence the positive SP rise today. I have also increased my holding again although fairly high risk owing to the small size of the company and short lead time for visible orders.
Well it looks like you called it about right it is does not look like it will hit my sub 80 buy target. Going off topic I have never heard of the walker method what do you make of DJAN I bought at £40.24 & £44.55 but they still look good value to me. Good luck with CRE going forward.
Agree with much of your post. Do not agree with reasonable management imo it has been both poor and over rewarded with far to many generous option packages. It is vital management of businesses understand how value is created not by issuing equity but by jealously guarding it instead of the "heads I win tails you lose" self-issuance of share options which has happened at CRE on regular basis over the yrs. Cheap stocks are usually cheap for a reason a low PE tells you more about the quality of the business/management than its worth. However, I could see this becoming a takeover target if it gets cheap enough Havas own 6%. The management being replaced placed would also cause the SP to re-rate imo and of ii cannot by very happy with these latest results. However management here must be fully aware they need to deliver and I do not think they can afford another earnings miss after giving a positive outlook going forward for a 2nd time. I would consider buying below 80p but I think it may fall further as so many investors seem totally disenchanted with latest set of poor results. For a long term share holder CRE has been a serial under performer and for that reason my guess would be the SP settling between 70 & 75.
Please ignore the 1st "worded".
I thought the results were okay the trading statement could have been worded more positively worded but nonetheless the 10% fall seems well overdone a small top up is in order.
IMO anyone waiting for a pull back is going to be disappointed I can see this steadily rising throughout 2014 as the earnings potential of the varicose treatment becomes evident could even become a takeover target.
Numpty update much appreciated bought a small holding for my SIPP today.
A 3rd director has now bought and the SP is up 4.48%. Alent was originally part of Cookson an engineering firm that was split up to form two companies so there is not much company history to go on. It is in the chemicals sector which also got a boost today fm Merck bidding for AZ Electronics at 53% premium to its SP. ALENT has seen a lot of director buying and also approx 21% of the company has been purchased by Cevian Capital who have a representative on the board. IMO it is always good to have your aligned investment aligned to both the directors and a 3rd party of obliviously keen for a return on a very large investment. IMO a strong buy but as always DYOR.